Armatus Bio Develops Scalable Potency Assay Platform for Gene Silencing Therapies
Armatus Bio has introduced a scalable potency assay platform to accelerate the development of gene silencing therapies for neuromuscular diseases such as facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease type 1A (CMT1A). The platform, detailed in a publication in Molecular Therapy Advances, addresses the lack of standardized assays for product consistency and regulatory compliance. By engineering human cell lines with a universal AAV receptor and a luciferase-based reporter system, the platform provides quantifiable, dose-dependent readouts and streamlined assay development. 
